Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 14/20 | 1.00 |
| ▸ | METTL3 | Q86U44 | 2/20 | 0.79 |
| ▸ | MEN1 | O00255 | 2/20 | 0.75 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.75 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.75 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.75 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.75 |
| ▸ | TTR | P02766 | 1/20 | 0.75 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.75 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.75 |
| ▸ | FABP2 | P12104 | 1/20 | 0.75 |
| ▸ | RXRA | P19793 | 1/20 | 0.75 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.75 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.75 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.75 |
| ▸ | PDE4A | P27815 | 1/20 | 0.75 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.75 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.75 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.75 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23386249 | 0.88 | METTL3 (1.00) | PTGS2METTL3MEN1MAPK1KMT2A | |
| Meclofenamic Acid SCHEMBL11543781 | 0.86 | PTGS2 (1.00) | PTGS2METTL3MEN1MAPK1KMT2A | |
| Meclofenamic Acid SCHEMBL29379636 | 0.86 | PTGS2 (1.00) | PTGS2METTL3MEN1MAPK1KMT2A | |
| SCHEMBL7346365 | 0.86 | PTGS2 (0.79) | PTGS2METTL3MEN1MAPK1KMT2A | |
| Meclofenamic Acid SCHEMBL29373906 | 0.86 | PTGS2 (1.00) | PTGS2METTL3MEN1MAPK1KMT2A | |
| Meclofenamic Acid SCHEMBL106 | 0.86 | PTGS2 (1.00) | PTGS2METTL3MEN1MAPK1KMT2A | |
| SCHEMBL11013086 | 0.86 | PTGS2 (0.79) | PTGS2METTL3MEN1MAPK1KMT2A | |
| SCHEMBL9734451 | 0.85 | PTGS2 (1.00) | PTGS2METTL3MEN1MAPK1KMT2A | |
| SCHEMBL10529901 | 0.85 | METTL3 (0.80) | PTGS2METTL3MEN1MAPK1KMT2A | |
| SCHEMBL10531397 | 0.85 | PTGS2 (0.73) | PTGS2METTL3MEN1MAPK1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120263650-A1 | NITROXIDE MODIFIED NON-STEROIDAL ANTI-INFLAMMATORY COMPOUNDS AND USES THEREOF IN THE TREATMENT AND PREVENTION OF DISEASES OR DISORDERS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH | 2012-10-18 | — | — | US | disclosed |
| US-5462952-A | Have activity as inhibitors of 5-lipoxygenase and/or cyclooxygenase | WARNER-LAMBERT COMPANY (US) | 1995-10-31 | — | — | US | disclosed |
| US-5112846-A | Nonsteroidal antiinflammatory agents | WARNER-LAMBERT COMPANY (US) | 1992-05-12 | — | — | US | disclosed |
| US-5075330-A | N-hydroxyamide, N-hydroxythioamide, N-hydroxyurea, and N-hydroxythiourea derivatives of selected NSAIDS as antiinflammatory agents | WARNER-LAMBERT CO. (US) | 1991-12-24 | — | — | US | disclosed |
| US-5066668-A | Enzyme inhibitors, cyclooxygenase and lipoxygenase, mixture with nonsteroid antiinflammatory agent | WARNER-LAMBERT CO. (US) | 1991-11-19 | — | — | US | disclosed |
| US-4981865-A | N-hydroxyamide, N-hydroxythioamide, hydroxyurea, and N-hydroxythiourea derivatives of selected nsaids as antiinflammatory agents | WARNER-LAMBERT CO. (US) | 1991-01-01 | — | — | US | disclosed |
| EP-0401857-A2 | Fenamate 1,3,4-thiadiazoles and 1,3,4-oxadiazoles as antiinflammatory agents | WARNER-LAMBERT COMPANY (US) | 1990-12-12 | — | — | EP | disclosed |
| US-4962119-A | Inhibit lipoxygenase, cyclooxygenase | WARNER-LAMBERT COMPANY (US) | 1990-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120263650-A1 | NITROXIDE MODIFIED NON-STEROIDAL ANTI-INFLAMMATORY COMPOUNDS AND USES THEREOF IN THE TREATMENT AND PREVENTION OF DISEASES OR DISORDERS | NOS1, NOS3, PTGS1 | PTGS2 12/4885METTL3 2478/4885MEN1 2199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.